biostudies-literatureUnknown334(11)DIAMOND Study Group<h4>Importance</h4>With the programmed cell death protein 1 (PD-1) blockade toripalimab, omitting highly toxic concurrent cisplatin may be feasible for nasopharyngeal carcinoma (NPC) without compromising survival.<h4>Objective</h4>To evaluate the efficacy and safety of toripalimab incorporated into induction chemotherapy and radiotherapy, without concurrent cisplatin, for locoregionally advanced NPC.<h4>Design, setting, and participants</h4>Open-label, multicenter, randomized phase 3 clinical trial conducted from August 2021 to July 2022 at 13 hospitals in China, enrolling 532 patients with T4N1M0 or T1-4N2-3M0 NPC; 400 (75.2%) completed the trial per protocol. The final date of follow-up was March 21, 2025.<h4>Interventions</h4>Patients were randomly assigned to either the standard therapJAMA973-983https://www.ebi.ac.uk/biostudies/studies/S-EPMC12371549biostudies-literatureToripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.PMC12371549She LJTang XHHuang JLu LXZhang NHuang LGuo RWang XHChen XZJin FGuo LTang LLQiang MYZang SBLiu LZWang YSu YLin AHLiu LTWu YOuyang PYShen LFLiu WXLi YQHuang HLChen LHong SBJie YSXu CZeng WHZou GRLi LSun YYe ZLDu XJLi HJYang QHuang XQLin LWei HMYang KYLi JBZhu XDLiu NZhao HYHu DSLiu XLi YYXie FYDIAMOND Study GroupZeng YCTian LLv JWHu GYZhou GQPeng YLLi WFLiang XYDu ZMChen YPMao YPHuang YLong GXXiang YQYun JPZhang YMa JLiang YLXiao SWLi JGHan FfalseToripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.<h4>Importance</h4>With the programmed cell death protein 1 (PD-1) blockade toripalimab, omitting highly toxic concurrent cisplatin may be feasible for nasopharyngeal carcinoma (NPC) without compromising survival.<h4>Objective</h4>To evaluate the efficacy and safety of toripalimab incorporated into induction chemotherapy and radiotherapy, without concurrent cisplatin, for locoregionally advanced NPC.<h4>Design, setting, and participants</h4>Open-label, multicenter, randomized phase 3 clinical trial conducted from August 2021 to July 2022 at 13 hospitals in China, enrolling 532 patients with T4N1M0 or T1-4N2-3M0 NPC; 400 (75.2%) completed the trial per protocol. The final date of follow-up was March 21, 2025.<h4>Interventions</h4>Patients were randomly assigned to either the standard therap2025-01-01T00:00:00Z2025 Sep2026-07-16T13:02:06.957Z2026-07-09T10:56:34.852ZS-EPMC123715494083937210.1001/jama.2025.13205